Overexpression of LAPTM4B-35 promotes growth and metastasis of hepatocellular carcinoma in vitro and in vivo.

LAPTM4B-35, encoded by Lysosomal protein transmembrane 4 beta (LAPTM4B) is over-expressed in more than 71% of hepatocellular carcinomas (HCCs) and associated with prognosis of the patients. But the exact role and molecular mechanism in HCC have not been determined. In this study, we explored the effects and mechanisms of LAPTM4B-35 on tumor growth and metastasis in vitro and in vivo by overexpression and depletion of LAPTM4B in HCC HepG2 and Bel7402 cells. These findings suggest that overexpression of LAPTM4B-35 plays a critical role in the growth and metastasis of HCC, and LAPTM4B-35 may therefore be a therapeutic target for HCC.

[1]  Y Taya,et al.  Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. , 2000, Genes & development.

[2]  Andreas Sewing,et al.  Myc activation of cyclin E/Cdk2 kinase involves induction of cyclin E gene transcription and inhibition of p27Kip1 binding to newly formed complexes , 1997, Oncogene.

[3]  M. Yu,et al.  Epidemiology of hepatocellular carcinoma. , 2000, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[4]  D. E. Anderson,et al.  Two 14-3-3 binding motifs are required for stable association of Forkhead transcription factor FOXO4 with 14-3-3 proteins and inhibition of DNA binding. , 2003, Biochemistry.

[5]  B. Amati,et al.  Myc and the cell cycle. , 1998, Frontiers in bioscience : a journal and virtual library.

[6]  L. M. Facchini,et al.  Myc induces cyclin D1 expression in the absence of de novo protein synthesis and links mitogen-stimulated signal transduction to the cell cycle. , 1994, Oncogene.

[7]  J. Westermarck,et al.  Mechanisms of MYC stabilization in human malignancies , 2008, Cell cycle.

[8]  G. Laurie,et al.  Basement membrane complexes with biological activity. , 1986, Biochemistry.

[9]  A. Burroughs,et al.  Hepatocellular carcinoma , 2003, The Lancet.

[10]  G. Evan,et al.  Suppression of Myc-Induced Apoptosis in β Cells Exposes Multiple Oncogenic Properties of Myc and Triggers Carcinogenic Progression , 2002, Cell.

[11]  J. Rui,et al.  Expression of lysosome-associated protein transmembrane 4B-35 in cancer and its correlation with the differentiation status of hepatocellular carcinoma. , 2005, World journal of gastroenterology.

[12]  Shinji Tanaka,et al.  Molecular targeted therapies in hepatocellular carcinoma. , 2012, Seminars in oncology.

[13]  J. Oh,et al.  Reciprocal expressions of cyclin E and cyclin D1 in hepatocellular carcinoma. , 2001, Cancer letters.

[14]  Y Iwamoto,et al.  A rapid in vitro assay for quantitating the invasive potential of tumor cells. , 1987, Cancer research.

[15]  M. Hidalgo,et al.  Treating cancer by blocking cell signals. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Joseph R. Nevins,et al.  A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells , 2004, Nature Cell Biology.

[17]  C. Sawyers,et al.  The phosphatidylinositol 3-Kinase–AKT pathway in human cancer , 2002, Nature Reviews Cancer.

[18]  S. Thorgeirsson,et al.  Molecular pathogenesis of human hepatocellular carcinoma , 2002, Nature Genetics.

[19]  Lewis C Cantley,et al.  The phosphoinositide 3-kinase pathway. , 2002, Science.

[20]  W. Sellers,et al.  Drug discovery approaches targeting the PI3K/Akt pathway in cancer , 2008, Oncogene.

[21]  M. Roussel,et al.  Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. , 1998, Genes & development.

[22]  R. Medema,et al.  AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1 , 2000, Nature.

[23]  M. Loda,et al.  Acquired expression of p27 is a favorable prognostic indicator in patients with hepatocellular carcinoma. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[24]  R. Eisenman,et al.  Deconstructing myc. , 2001, Genes & development.

[25]  P. Schirmacher,et al.  Protumorigenic overexpression of stathmin/Op18 by gain‐of‐function mutation in p53 in human hepatocarcinogenesis , 2007, Hepatology.

[26]  X. Nie,et al.  LAPTM4B-35 overexpression is a risk factor for tumor recurrence and poor prognosis in hepatocellular carcinoma , 2010, Journal of Cancer Research and Clinical Oncology.

[27]  Dajun Yang,et al.  MI-63: A novel small-molecule inhibitor targets MDM2 and induces apoptosis in embryonal and alveolar rhabdomyosarcoma cells with wild-type p53 , 2009, British Journal of Cancer.

[28]  J. Rui,et al.  [Identification and characterization of LAPTM4B encoded by a human hepatocellular carcinoma-associated novel gene]. , 2003, Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences.